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Abstract
Background: Age-associated epigenetic changes are implicated in aging. Notably, age-associated DNA methylation
changes comprise a so-called aging “clock”, a robust biomarker of aging. However, while genetic, dietary and drug
interventions can extend lifespan, their impact on the epigenome is uncharacterised. To fill this knowledge gap, we defined
age-associated DNA methylation changes at the whole-genome, single-nucleotide level in mouse liver and tested the impact
of longevity-promoting interventions, specifically the Ames dwarf Prop1df/df mutation, calorie restriction and rapamycin.
Results: In wild-type mice fed an unsupplemented ad libitum diet, age-associated hypomethylation was enriched at super-
enhancers in highly expressed genes critical for liver function. Genes harbouring hypomethylated enhancers were enriched
for genes that change expression with age. Hypermethylation was enriched at CpG islands marked with bivalent activating
and repressing histone modifications and resembled hypermethylation in liver cancer. Age-associated methylation changes are
suppressed in Ames dwarf and calorie restricted mice and more selectively and less specifically in rapamycin treated mice.
Conclusions: Age-associated hypo- and hypermethylation events occur at distinct regulatory features of the genome.
Distinct longevity-promoting interventions, specifically genetic, dietary and drug interventions, suppress some age-
associated methylation changes, consistent with the idea that these interventions exert their beneficial effects, in part,
by modulation of the epigenome. This study is a foundation to understand the epigenetic contribution to healthy
aging and longevity and the molecular basis of the DNA methylation clock.
Background
Genetic, dietary and drug interventions can enhance lon-
gevity and suppress age-associated disease, such as cancer.
Prominent genetic interventions that robustly extend
longevity and healthspan in mammals include those that
decrease growth hormone (GH) and insulin-like growth
factor (IGF) signalling; for example, Ames dwarf mice
live more than 50% longer than their wild-type siblings
[1]. These diminutive mice result from a point muta-
tion in a gene (Prop1df/df ) that drives development of
the pituitary gland, so that mutant mice are deficient in
specific hormones. The GH deficiency, in particular,
has been shown to underlie their enhanced health span
and extended lifespan. Ames mice are highly insulin-
sensitive, resistant to some stresses and the incidence
of cancer is delayed [2–4]. Dietary and drug interven-
tions that extend lifespan include calorie restriction
(CR) and the mTOR inhibitor rapamycin [5]. Like the
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Ames dwarf mutation, CR and rapamycin also suppress and/
or delay the incidence of cancer [5–7]. A detailed understand-
ing of how these interventions exert their beneficial effects is
essential to develop strategies to promote healthy aging in
humans [8]. Currently, these interventions are thought to
exert their effects by related and interconnected effects on
some or all of the following: genome stability, the epige-
nome, telomere attrition and/or function, protein quality
control, mitochondrial function, nutrient sensing, cellular
senescence, stem cell exhaustion, cellular stress responses
and altered intercellular communication [9]. Of note, the
effects of longevity promoting interventions on the epige-
nome, a key determinant of cell phenotype, are poorly
understood.
Aging is associated with changes to the epigenome
[10, 11]. These changes include age-associated accumu-
lation of histone variants, for example histone H3.3 in
neurons and macroH2A in lung, liver and muscle, as
well as other chromatin-associated proteins and changes
to histone and DNA modifications [12–14]. Aging also
affects specific gene regulatory elements, such as en-
hancers, promoters and CpG islands [15–23]. Under-
scoring the importance of such age-associated epigenetic
changes, recent human studies have identified collec-
tions of specific CpGs whose age-associated change in
methylation status in multiple tissues correlates strongly
with chronological age. An advanced methylation age
compared to actual chronological age is thought to re-
flect accelerated biological age and is linked to increased
mortality [24–28].
Age-associated epigenetic changes are not just bio-
markers or passengers in the aging process, but can be
causative in control of lifespan [29–31]. For example, in
yeast, accumulation of H4K16ac at subtelomeric regions
promotes replicative aging, while inactivation of the chro-
matin remodeler Iswi2p or the H3K36me2/3 demethylase
Rph1p extends lifespan [29, 32, 33]. Decreased H3K4
methyltransferase activity can extend worm lifespan in a
germline dependent manner [30]. In mice, muscle stem
cells from old mice exhibit elevated repressive H3K27me3
at repressed histone genes [34], perhaps responsible for
decreased proliferative potential of aged stem cells com-
pared to young stem cells [35]. Mouse haematopoietic
stem cells (HSCs) also exhibit changes in DNA methyla-
tion with age, including a small net hypermethylation both
globally and at CpG islands [36, 37]. Some of these
changes in aged cells are thought to promote expres-
sion of self-renewal genes and impair expression of
differentiation genes, including lymphoid genes. This
can contribute to the characteristic phenotypes of aged
HSCs, such as increased number, decreased function
and a predisposition to myeloid differentiation [36].
Epigenetic changes linked to aging also impact spe-
cific diseases of aging, including cancer. While some
age-associated epigenetic changes, such as increased
abundance of histone modification H4K20me3 [10] and
decreased H3K27me3 [38, 39], may activate tumour
suppressor mechanisms and prevent cancer, others may
be tumour promoting. Like cancer, aged tissue has been
reported to exhibit global DNA hypomethylation and
more focal hypermethylation at CpG islands [10]. Most
notably, so-called bivalent gene promoters, marked with
both activating H3K4me3 and repressing H3K27me3
(hence “bivalent”) in embryonal stem (ES) cells, acquire
DNA methylation in aged tissues and are also methylated
and stably silenced in cancer [15–19]. In ES cells, these
bivalent-marked genes are thought to be poised for activa-
tion due to loss of the repressive H3K27me3 mark during
stem and progenitor cell differentiation and development.
By virtue of their pro-differentiation functions these genes
tend to have tumour suppressor-like properties, meaning
that their methylation and stable silencing may promote
proliferation, self-renewal and malignancy. In the haem-
atopoietic system, some CpG islands progressively in-
crease methylation from young to old to neoplasia,
namely myelodysplastic syndrome (MDS) and ultimately
acute myeloid leukemia [40]. Sf3b1, the mouse ortholog of
a gene frequently mutated in human MDS, is methylated
and underexpressed in aged mouse HSCs [36]. Hence,
age-associated methylation changes might predispose to
transformation of aged cells by promoting silencing of
tumour suppressor genes.
Given this strong and accumulating evidence that epi-
genetic events are important determinants of lifespan
and predisposition to disease, we set out to ask whether
genetic, dietary and drug interventions that promote
healthy aging and longevity suppress age-associated
DNA methylation changes.
Methods
Ames dwarf mice were derived from a closed colony
with a heterogeneous background (over 25 years) at the
University of North Dakota [41]. Dwarf mice (and cor-
responding wild type (WT)) were generated by mating
either homozygous (df/df ) or heterozygous (df/+) dwarf
males with heterozygous females (df/+). Non-genotypic
intervention studies (rapamycin and CR) utilised genet-
ically heterogeneous WT UM-HET3 mice bred at the
University of Michigan. One cohort was given encapsu-
lated rapamycin (42 parts per million (ppm)) from
4 months of age, and another group a CR diet initiated at
4 months of age (these mice received 60% of the intake of
their age-matched controls after a two week run-in period
at 80%). All cohorts contained four replicates (four mice).
Liver tissue was collected at 2 and 22 months of age and
DNA isolated using a DNeasy Blood and Tissue Kit (Qia-
gen). Hepatocellular carcinoma (HCC) is a relatively com-
mon disease of aging in mice. Hence, to avoid distortion
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of our data by neoplastic tissue, aged mice were sacrificed
at 22 months (before HCC is typically apparent) and livers
with overt signs of neoplasia were excluded from analysis.
Where whole-genome bisulphite sequencing (WGBS-seq)
was performed (by BGI, Shenzen), samples underwent a
standard protocol of sonication, DNA-end repair and
ligation of methylated adapter sequences prior to bisul-
phite conversion using a ZYMO EZ DNA Methylation-
Gold Kit (Zymo Research) and then 90-bp, paired-end se-
quencing on the Illumina Hi-Seq 4000 platform. Se-
quenced reads were aligned to the reference genome
(mm9) and methylation status of CpGs determined using
Bismark and Bowtie2 [42, 43]. The bioinformatics process
involved read quality assessment via FastQC, read trim-
ming using the package Trim-Galore with alignment, read
de-duplication and methylation context extraction via the
Bismark suite [42]. CpG dyads were collapsed by combin-
ing the methylated and unmethylated scores at each dyad
locus. The mouse genome contains approximately 42 mil-
lion CpG loci (mm9)—or 21.3 million CpG dyads. We
achieved sufficient coverage to represent between 94 and
96% of the dyads in the young and old, WT and Ames
dwarf dataset, with a mean coverage of 6.96 methylation
calls per site (four biological replicates per cohort (approxi-
mately 15-fold coverage per genome), to yield approxi-
mately 1500 Gbp of data (Additional file 1: Table S1)).
Despite sequencing CR and rapamycin intervention data
with reduced coverage, we still observe 86–89% of all map-
pable CpG dyads with a mean coverage of 4.37 reads per
loci. To identify differentially methylated CpG sites, a two-
tailed Fisher exact test (FET) was used with p value correc-
tion using a Benjimini–Hochberg (BH)-false discovery rate
(FDR) function at a rate of 5% where coverage surpassed a
threshold of ten overlapping reads. To identify differentially
methylated regions (DMRs), we used a sliding window-
based approach operating at a range of 500 bp. At each
window, a two-tailed FET was performed to determine
DMR significance alongside a chi-squared test of het-
erogeneity across the four mouse replicates within each
cohort. Both chi-squared and FET tests were multi-
sample corrected using BH-FDR with DMRs selected on
the basis of significant (p < 0.05) BH-FDR-corrected FET
score and non-significant intra-cohort heterogeneity via
the FDR-corrected chi-squared test. We then divided
DMRs into hyper- and hypomethylated based on
positive or negative changes in their respective methy-
lation relative to their control. To determine the signifi-
cance of the overlaps between regions or features, we
used a permutation-based approach to assess significant
enrichment over equally sized, randomly generated
regions and calculated fold enrichments based on how
these regions overlap compared to an expected
(random) model level of intersection. We validated
findings using MeDIP-seq, an enrichment based assay
that enriches methylated DNA fragments via immun-
oprecipitation with anti-methyl-cytosine antibodies
[44]. Additional details, including RNA- and ChIP-seq
analysis information, are available in Additional file 2:
Supplementary methods.
Results
The epigenomes of wild-type and Ames dwarf mice
diverge with age
To investigate the relationship between age-associated
epigenetic changes and healthy aging and longevity, we
first set out to compare the DNA methylome of liver
from young and old male WT and long-lived Ames
dwarf mice. We selected liver for this study because our
previous studies showed differences in liver in expres-
sion of DNA methyltransferases (DNMTs) between WT
and Ames mice and young and old mice [45]. Also, a
single cell type, the hepatocyte, comprises ~80% of liver
mass, and the epigenome of mouse liver has been exten-
sively characterised, thereby aiding downstream analysis
of the methylome in the context of the wider epigenetic
landscape. We performed WGBS-seq on the livers of
young adult (2 months of age) and old (22 months of
age) Ames dwarf and WT mice. We found that global
levels of methylation across all CpGs in the genome
were highly similar between all age groups, mouse geno-
types and replicates (Fig. 1a). This was also apparent
from viewing whole-chromosome methylation profiles
on the UCSC genome browser (Fig. 1b). However princi-
pal component analysis (PCA) of the data (percentage
methylation per CpG) suggested that local differences in
methylation were present, as cohorts separated well on
the first and/or second principal components (12.38 and
7.64% of the respective cumulative variance) (Fig. 1c).
Previous studies showed that epigenomes become
more divergent with age [46]. Therefore, we set out to
assess differences between WT and Ames dwarf mice at
2 months and 22 months’ of age. We determined those
CpGs differentially methylated between genotypes (i.e.
between WT and Ames dwarf mice (gCpGs)). This was
performed separately in both the young and old mice,
using a Fisher’s exact test method at 5% FDR (“Methods”).
In dwarf mice, compared to WT mice, approximately ten
times more CpGs were hypermethylated than were hypo-
methylated (Fig. 1d). Strikingly, we observed a larger num-
ber of significantly hypermethylated gCpGs (Fig. 1d) in
the older mice compared to the young, suggesting that
the WT and Ames mice exhibit more epitype differ-
ences with age. These differences were also visualised
by identifying all gDMRs for both the young and the
old mice using a dynamic 500-bp sliding window and
Fisher’s exact test method at 5% FDR and also remov-
ing any DMRs that were not consistent across all four
replicates (“Methods”; Fig. 1e; Additional file 3: Table S1e).
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We observed a significant increase in hypermethylated
gDMRs, while the increase in hypomethylated gDMRs
was not significant (Fig. 1e; Additional file 3: Table S1e).
The consistency of the gDMRs across all four replicates
within each cohort was confirmed in both gDMR heat-
maps (Fig. 1f) and kernel smoothed methylation plots of
representative gDMRs (Fig. 1g). Together, these data
establish that between the Ames and WT mice there are
more than 20,000 DMRs, and the number of these epigen-
otype differences increases markedly with age.
The Ames dwarf epigenome appears more stable and
buffered against age-associated hypomethylation
To further investigate these age-associated epigenotype
differences between the WT and dwarf mice, we char-
acterised age-associated differentially methylated CpGs
a) b)
c)
f)
g)
d) e)
Fig. 1 The epigenomes of wild-type and Ames dwarf mice diverge with age. a Global percentage methylation per liver sample, for 2-month-old
wild-type (WTY), 22-month-old wild-type (WTO), 2-month-old Ames dwarf (DY) and 22-month-old Ames dwarf (DO) mice. All p > 0.05 (two tailed t-test
on arcsine transformed proportions). b UCSC genome browser trace of percentage methylation over chromosome 1, showing pooled WTY (light blue),
WTO (dark blue), DY (light red), DO (dark red) replicate tracks. c Principal component analysis of CpG percentage methylation, for WTY (light blue), WTO
(dark blue), DY (light red) and DO (dark red) liver samples. Principal component (PC)1 proportion of variance = 12.38%, and PC2 proportion of variance
= 7.64%. d The number of significantly differentially methylated CpGs (5% FDR, Fisher’s exact test) between four pooled WT and four pooled Ames
dwarf replicates (gCpGs) in liver of 2-month-old (young) and 22-month-old (old) mice. Hyper- and hypomethylated gCpGs are higher and lower in
Ames dwarf mice, respectively. e As d but showing significantly differentially methylated regions (gDMRs; 5% FDR, Fisher’s exact test, 500-bp
windows). Regions of heterogeneity (chi-squared test <0.05) across the four replicates in each cohort were removed. DY-WTY versus DO-WTO
hypermethylation, p < 0.05 (marked with an asterisk). See also Additional file 3: Table S1e. f The percentage methylation across all 2-month-old (left)
and 22-month-old (right) gDMRs. Replicate samples (four mouse livers) are in rows and the gDMRs in columns. The intensity of the heatmap represents
column scaled percentage methylation (Z-score), with values ranging from lower to higher methylation shown as blue to yellow. g Kernel smoothed
line plots of selected gDMRs, ±5 kb. WTY, DY, WTO and DO replicates are represented by solid blue, solid red, dashed blue and dashed red lines,
respectively. DMRs are highlighted in pink and CpGs in black
Cole et al. Genome Biology  (2017) 18:58 Page 4 of 16
(i.e. CpGs whose methylation status changes with age
in either WT or Ames dwarf mice (aCpGs)) in both the
WT and dwarf mice using a Fisher’s exact test method
at 5% FDR (“Methods”). Strikingly, we observed roughly
three times more significant aCpGs in the WT than the
dwarf mice (Fig. 2a), suggesting that the methylome of
dwarf mice is more stable through chronological aging.
Similarly, we detected less than half the number of
aDMRs in dwarf mice compared to WT mice (Fig. 2b;
Additional file 3: Table S2b). Changes in the aDMRs
were consistent across all four replicates within each
cohort, as confirmed by aDMR heatmaps (Fig. 2c, d)
and representative kernel smoothed methylation plots
(Fig. 2e). Although we observed significantly more
aDMRs in the WT than the dwarf mice, the magnitude
of the methylation change per DMR was comparable in
the WT and dwarf mice (Fig. 2f ). To confirm these
aDMR loci in other mouse cohorts and strains, we per-
formed WGBS-seq of whole liver from 2-month-old
and 22-month-old female UM-HET3 mice from the
NIA Intervention Testing Program (ITP) cohorts (four
mouse replicates per age group, approximately 5×
coverage per replicate) (Additional file 4: Table S2).
Global methylation was comparable to Ames dwarf and
corresponding WT and, again, between young and old
(compare Fig. 1a and Additional file 5: Figure S1a).
However, PCA again separated the young and old UM-
HET3 mice, indicative of their differential methylation
(Additional file 5: Figure S1b). Hence, aDMRs were
identified between young and old UM-HET3 mice
(“Methods”). The extent of overlap of the two sets of
WT hypomethylated aDMRs (i.e. the WT used for
comparison to Ames dwarf throughout and WT UM-
HET3 (see “Methods”)) was much greater than ex-
pected from random overlap and highly significant. The
same was the case for the two sets of hypermethylated
aDMRs. However, there was minimal overlap between
hypermethylated and hypomethylated aDMRs (Fig. 2g).
In sum, aging of the liver generates thousands of
discrete aDMRs. Significantly, the epigenome of WT
mice exhibits many more such regions than that of
Ames dwarf mice, suggesting that the Ames dwarf epi-
genome is more stable with chronological age than the
WT epigenome.
While many aDMRs were restricted to WT mice,
other aDMRs were restricted to Ames mice or were
shared by both genotypes (Additional file 5: Figure S1c).
Plots of mean percentage methylation per mouse liver
sample at each subset of DMR (i.e. WT hypermethylated
aDMRs (Additional file 5: Figure S1d), dwarf hypermethy-
lated aDMRs (Additional file 5: Figure S1e) and hyper-
methylated aDMRs shared between WTand dwarf (Fig. 2h)
confirmed the DMR subsets and consistency between
mouse replicates (Fig. 2h, i; Additional file 5: Figure S1d–g).
For example, at shared hypermethylated aDMRs,
methylation increased comparably with age in both WT
and dwarf mice (Fig. 2h). The methylation changes at
hypomethylated aDMRs were particularly interesting.
At the hypomethylated aDMRs restricted to WT mice,
the young and old Ames mice both showed methylation
comparable to the young WT mice (Additional file 5:
Figure S1f ), while at the hypomethylated aDMRs re-
stricted to the Ames mice, the young and old WT mice
both showed methylation comparable to the older Ames
mice (Additional file 5: Figure S1g). At shared hypomethy-
lated aDMRs, while the magnitude of the change was
comparable between WT and Ames, the dwarf mice
showed consistently higher methylation than the WT in
both age groups (Fig. 2i). This phenomenon was also ap-
parent in the population of individual aDMRs, which
showed higher methylation in dwarf in both young and
old mice (i.e. below right of the 45° diagonal in both plots)
and an age-associated loss of methylation in both WT and
dwarf (i.e. closer to zero on both x and y axes in old mice)
(Additional file 5: Figure S1h). At representative shared
hypomethylated aDMRs, methylation declined with age in
both WT and dwarf mice but began at higher levels in the
young dwarf (Fig. 2j). In sum, in dwarf mice, hypomethy-
lated aDMRs were biased towards a higher methylation
level. This is most notable at hypomethylated aDMRs
shared between WT and Ames dwarf mice, where the lat-
ter exhibited a higher initial level of methylation in young
animals, thus potentially buffering them against the effects
of age-associated hypomethylation.
Hypomethylated aDMRs are enriched at intragenic
enhancers in highly expressed liver-specific genes
Next, we set out to define the location of the hypo-
methylated aDMRs across the genome. First, we asked
how the WT and dwarf hypomethylated aDMRs are dis-
tributed across a collection of genomic features. Although
there were approximately twice as many hypomethylated
aDMRs in WT mice than Ames mice (Figs. 2b and 3a),
the proportionate distribution of these aDMRs across
features of the genome was very similar (Fig. 3a). Most
commonly, the hypomethylated aDMRs overlap genes
(~60%) and introns (~50%), although they are only mod-
estly enriched at these features, relative to the abundance
of these features in the genome (Fig. 3a). Least commonly,
they overlapped CpG islands (<1%) and LINEs (~5%), and
were moderately depleted at these features (Fig. 3a). To
further investigate, we took advantage of the many pub-
licly available datasets for mouse liver and expanded
this distribution analysis to include several ENCODE
adult mouse liver histone modification ChIP-seq data-
sets (Fig. 3a; Additional file 5: Figure S2a; Additional
file 6: Table S3; Additional file 7: Table S4). Strikingly,
we observed that ~55 and ~40% of all hypomethylated
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Fig. 2 (See legend on next page.)
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aDMRs overlapped the enhancer modifications H3K4me1
and H3K27ac, with an enrichment of seven- to ninefold
(p < 0.001; Fig. 3a). There was a more modest overlap and
enrichment, or even depletion, at other histone modifica-
tions, notably the gene body modification H3K36me3 and
the repressive mark H3K27me3 (Fig. 3a). In line with this
enrichment at H3K4me1 and H3K27ac, there was marked
overlap and enrichment at designated mouse liver
enhancers, regions marked by both H3K4me1 and
H3K27me3 (“Enhancers” in Fig. 3a). Of the ~47,000 iden-
tified mouse liver enhancers, 8230 and 4702 contained a
hypomethylated aDMR in WT and dwarf mice, respect-
ively (Fig. 3b), corresponding to a substantial fraction of
all enhancers. Of these, a significant number (2037) were
hypomethylated in both genotypes (fold enrichment of
153, p < 0.001; Fig. 3b). Shared hypomethylated aDMRs
(Fig. 2i) are apparently generally buffered from methyla-
tion loss in the Ames mice (Fig. 3c, d). There were 6193
enhancers that contained hypomethylated aDMRs only in
WT mice (Fig. 3b). These showed more marked loss of
methylation in aged WT mice compared to aged dwarf
mice (Fig. 3e).
Since the majority of the hypomethylated enhancers
are contained within genes (Fig. 3a; Additional file 5:
Figure S2b), we also assessed the relationship between
enhancer hypomethylation and gene expression as de-
termined by RNA-seq (Additional file 8: Table S5).
The methylation loss per enhancer CpG was inde-
pendent of expression of the gene harbouring the
enhancer (Additional file 5: Figure S2c). However,
hypomethylated enhancers appeared more abundant,
longer and to cover a greater fraction of the gene in
highly expressed genes compared to lowly expressed
genes (Fig. 3f; Additional file 5: Figure S2d, e). Consistent
with their high level of expression in liver, in both WTand
dwarf mice the genes harbouring hypomethylated
enhancers were highly enriched for liver specific genes
(Additional file 5: Figure S2f). Moreover, of 30 publicly
available adult mouse liver transcription factor ChIP-seq
datasets (Additional file 5: Figure S2a), the factors most
enriched for binding to hypomethylated aDMRs in both
genotypes included key regulators of liver function (e.g.
CEBPB, GR (NR3C1), RXRA, PPARA, CEBPA, HNF3A
and HNF4A; p < 0.001; Fig. 3a). Recently, super-enhancers
have been defined as clusters of enhancers that are densely
bound by master transcription regulators and control
expression of critical tissue-specific genes [47]. Re-
markably, enhancers hypomethylated during aging were
greatly enriched at such super-enhancers (Fig. 3g;
Additional file 3: Table S3g). Many of these trends were ex-
acerbated in WT mice compared to Ames dwarf mice
(Fig. 3f, g; Additional file 5: Figure S2d, e). There was a sig-
nificant overlap of hypomethylated genic enhancers and
changes in expression of linked genes, although the vast
majority of genes containing hypomethylated enhancers
did not significantly alter expression (Additional file 9:
Table S6). We conclude that hypomethylated aDMRs
are most abundant at genes, introns and enhancers and
disproportionately enriched at genic super-enhancers in
highly expressed genes known to play a key role in liver
function. Although the distribution of hypomethylated
aDMRs is similar across the WT and dwarf epigenomes,
WT mice harbour a greater number of hypomethylated
genes and enhancers and the potentially disruptive effects
of hypomethylation [48] are seemingly buffered by a
higher level of methylation in young dwarf mice.
(See figure on previous page.)
Fig. 2 The Ames dwarf epigenome appears more stable and buffered against age-associated hypomethylation. a The number of significantly
differentially methylated CpGs (5% FDR, Fisher’s exact test) between 2 and 22-month-old WT (WT) and between 2- and 22-month-old Ames dwarf
(Dwarf) mice. Hyper- and hypomethylated aCpGs are higher and lower in 22-month-old mice, respectively. b The number of significantly differentially
methylated regions (aDMRs; 5% FDR, Fisher’s exact test, 500-bp windows) between 2- and 22-month-old mice for WT and Ames dwarf mice. Regions
of heterogeneity (chi-squared test <0.05) across the four replicates in each cohort were removed. Significance (empirical p value) at p < 0.05 is indicated
with an asterisk. See also Additional file 3. c The percentage methylation across all 2- (DY) versus 22-month-old (DO) Ames dwarf differentially
methylated regions (aDMRs). Replicate samples (four mouse livers) are in rows and the aDMRs in columns. The intensity of the heatmap represents
column scaled percentage methylation (Z-score), with values ranging from lower to higher methylation shown as blue to yellow. d The percentage
methylation across all 2- (WTY) versus 22-month-old (WTO) WT differentially methylated regions (aDMRs). Replicate samples (four mouse livers) are
in rows and the aDMRs in columns. Columns are scaled using Z-scores. The intensity of the heatmap represents Z-score, with values ranging from
negative to positive shown as blue to yellow. e Kernel smoothed line plots of selected aDMRs, ±5 kb. WTY, 2-month-old dwarf (DY), WTO and
22-month-old dwarf (DO) replicates are represented by solid blue, solid red, dashed blue and dashed red lines, respectively. DMRs are highlighted in pink
and CpGs in black. f The difference in mean percentage methylation per DMR (across all samples) between 22- and 2-month-old mice versus number
of aDMRs. WT aDMRs are shown in red and dwarf aDMRs in blue. g Ratio of observed/expected (random) overlap between WT (from a–d) and
UM-HET3 aDMRs. Hyper- and hypomethylated aDMRs are higher and lower in old mice, respectively. Significance (empirical p value) at p < 0.001 is
indicated with double asterisks. h Mean percentage methylation per replicate across all hypermethylated aDMRs common to both WT and Ames dwarf
mice (shared). WTY, WTO, DY and DO mice are shown in light blue, dark blue, light red and dark red, respectively. WTY versus WTO and DY versus DO at
p < 0.001 are indicated with double asterisks (two tailed t-test on arcsine transformed proportions). i As h but showing shared hypomethylated aDMRs.
WTY versus WTO, DY versus DO, WTO versus DO all p < 0.001 indicated with double asterisks and WTY versus DY p < 0.05 indicated with a single asterisk
(two tailed t-test on arcsine transformed proportions). j Kernel smoothed line plots of selected aDMRs common to both WT and dwarf mice, ±5 kb.
Pooled replicates for WTY, DY, WTO and DO are represented by solid blue, solid red, dashed blue and dashed red lines, respectively. DMRs are highlighted
in pink and CpGs in black
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Fig. 3 Hypomethylated aDMRs are enriched at intragenic enhancers in highly expressed liver-specific genes. a Clustered feature interaction maps
of spatial overlap between hypomethylated aDMRs (columns) and a selection of genomic, histone and transcription factor features (rows), showing
WT (WT; left) and dwarf (D; centre left) aDMRs. Red indicates an overlap between an aDMR and a feature and blue no overlap. Interaction map x-axes
are scaled by number of aDMRs. The percentage overlap (centre right) and fold enrichment observed/expected (random) overlap (right; units of fold)
for each feature are given. b The overlap between enhancers that contain hypomethylated aDMRs in WT and Ames dwarf mice. Enrichment of overlap
observed/expected 153-fold, p < 0.001. c Mean percentage methylation per replicate across enhancers that contain hypomethylated aDMRs in both
WT and dwarf mice. For 2-month-old WT (WTY; light blue), 22-month-old WT (WTO; dark blue), 2-month-old dwarf (DY; light red) and 22-month-old
dwarf (DO; dark red) mice. WTY versus WTO, DY versus DO, WTO versus DO all p < 0.001 (indicated with double asterisks) and WTY versus DY p < 0.05
(indicated with a single asterisk) (two tailed t-test on arcsine transformed proportions). d Kernel smoothed line plots of selected enhancers overlapping
hypomethylated aDMRs, ±5 kb. Replicates for WTY, DY, WTO and DO are represented by solid blue, solid red, dashed blue and dashed red lines,
respectively. DMRs are highlighted in pink and CpGs in black. H3K4me1 and H3K27ac enrichment (ChIP-seq) is indicated. e The percentage
methylation across all enhancers containing hypomethylated aDMRs unique to WT mice (6193 regions from Fig. 3b). Replicate samples (four
mouse livers) are in columns and the aDMRs in rows. The intensity of the heatmap represents row scaled percentage methylation (Z-score),
with values ranging from lower to higher methylation shown as blue to red. f Mean number of enhancer overlapping hypomethylated aDMRs
per gene for WT (blue) and Ames dwarf (red) mice. Genes are split into quartiles by expression (Q1 = highest, Q4 = lowest). Unexpressed genes
(FPKM = 0) are given (U). g Observed and expected overlap (in base pairs) of hypomethylated DMRs (WT, WT only; dwarf, dwarf only; shared,
shared between WT and dwarf) with super-enhancers; **P < 0.01
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Hypermethylated aDMRs are enriched at bivalent CpG
islands
We then wanted to characterise and determine the loca-
tion of hypermethylated aDMRs in the two genotypes of
mice. Taking the same approach as for the hypomethy-
lated aDMRs (Fig. 3a), we asked how the hypermethylated
aDMRs are spatially distributed and enriched across a
range of genomic features, histone modifications and tran-
scription factors (Fig. 4a; Additional file 5: Figure S3a).
Like hypomethylated aDMRs, there were more hyper-
methylated aDMRs in WT mice than Ames mice (Fig. 2b;
Additional file 3: Table S2b). However, in contrast to
hypomethylated aDMRs, the distribution of hypermethy-
lated aDMRs appeared different between the two geno-
types. This was initially apparent in a notable disparity
between fold enrichment of hypermethylated aDMRs in
WT and dwarf mice; at many features these aDMRs
tended to show lower fold enrichment or even deple-
tion in WT mice, particularly at transcription factor
binding sites (Fig. 4a; Additional file 5: Figure S3a). Closer
analysis showed that, while hypomethylated aDMRs were
similarly distributed in WT and dwarf between regions
marked or unmarked by histone modifications and tran-
scription factors, hypermethylated aDMRs in WT mice
were disproportionately at regions lacking histone modifi-
cations and transcription factors (Fig. 4b; Additional file 5:
Figure S3b). Most of these WT-specific hypermethylated
aDMRs were at regions of the genome that are relatively
highly methylated even in young mice (Additional file 5:
Figure S3c).
Across more richly annotated regions of the genome,
hypermethylated aDMRs were distributed similarly in WT
and Ames mice. In both genotypes, hypermethylated
aDMRs showed the greatest overlap with genes and in-
trons, although, like hypomethylated aDMRs, this was not
enriched considering the abundance of these features in
the genome (Fig. 4a). There was some enrichment of
hypermethylated aDMRs at H3K27ac and H3K4me1-
marked enhancers, although less so than for hypomethy-
lated aDMRs (Figs. 3a and 4a). However, in marked
contrast to hypomethylated aDMRs, hypermethylated
aDMRs showed large enrichment at CpG islands and
H3K4me3 and H3K27me3 marked bivalent chromatin
(p < 0.001; Fig. 4a). There was substantial overlap between
hypermethylated aDMRs at CpG islands and bivalent
chromatin (fold enrichment 1302 and p < 0.001; Fig. 4c;
Additional file 3: Table S4c), meaning that hypermethy-
lated aDMRs were enriched at bivalent marked CpG
islands (Fig. 4d). Hypermethylated bivalent regions over-
lapped significantly between genotypes, although there
were approximately 50% more in the WT than Ames mice
(Fig. 4e; Additional file 3: Table S4e). Interestingly, genes
linked to these bivalent CpG islands tended to be
expressed at relatively low levels (Fig. 4f), and there was
no enrichment for change in expression at these genes
(Additional file 9: Table S6). Gene ontology analysis
showed that many of these bivalent CpG islands are
linked to developmentally important genes that estab-
lish cell identity, similar to bivalent CpG islands in ES
cells [49] (Additional file 5: Figure S3d). In sum, hyper-
methylated aDMRs are enriched at bivalent CpG islands,
often of lowly expressed genes implicated in control of de-
velopment and cell identity, and age-associated methyla-
tion of these islands is substantially more frequent in WT
mice compared to Ames dwarf mice.
To confirm these key findings by an alternative meth-
odology, we performed MeDIP-seq (a whole-genome
sequencing-based method that isolates methylated
DNA sequences using an antibody to 5-methyl-cytosine
(5-mC) [50]) on a single replicate of young and old WT
and Ames dwarf mice. This allowed us to plot the relative
enrichment of methylated DNA reads at a set of regions,
in this case the hypomethylated enhancer aDMRs and
hypermethylated bivalent aDMRs that are shared between
WT and Ames dwarf mice (Figs. 3b and 4e). This
analysis confirmed a gain of methylation at hyper-
methylated bivalent regions and a decrease in me-
thylation at hypomethylated enhancers (Additional file 3:
Table S4a, b; Additional file 5: Figure S4a, b). Although
this MeDIP-seq method cannot resolve methylation status
at the single nucleotide level and our analysis of these data
is limited to a single replicate, this alternative approach
clearly validates key methylation changes in WT and
Ames dwarf mice.
Ames dwarf mice are resistant to cancer-like methylation
changes during aging
Bivalent CpG islands marked with H3K4me3 and
H3K27me3 in ES cells tend to be DNA methylated in
aged tissues and methylated and silenced in cancer
[15–19], suggesting that age-associated DNA methyla-
tion can be a precursor to methylation and stable silen-
cing in cancer. Therefore, we wanted to assess whether
CpG islands methylated with age in mouse liver are also
methylated on progression towards liver cancer and, if so,
whether this trend was suppressed in cancer-resistant
Ames dwarf mice. To do this, we analyzed DNA methy-
lation data, obtained by methylated DNA immunopre-
cipitation (MeDIP) followed by array hybridization,
from the late precancerous stages of HCC development
in 12-month-old Mdr2/Abcb4-knockout (Mdr2-KO)
male FVB strain mice, a well characterised model of
chronic inflammation-mediated HCC [51, 52]. These
mice typically exhibit chronic hepatitis from 2 months
and HCC at 12–18 months. Enhancers that were
hypomethylated in aged WT mice were comparably
methylated in WT and Mdr2-KO mice (Fig. 5a;
Additional file 3: Table S5a). In contrast, enhancers and
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bivalent CpG islands that were hypermethylated in aged
WT mice also tended to be hypermethylated in Mdr2-KO
mice (Fig. 5b, c; Additional file 3: Table S5b, c). This
phenomenon was particularly marked at bivalent CpG
islands. The same marked trend was also apparent at en-
hancers and bivalent CpG islands methylated with age in
dwarf mice (Fig. 5d–f; Additional file 3: Table S5d–f ). As
noted previously, however, fewer such aDMRs were in
Fig. 4 Hypermethylated aDMRs are enriched at bivalent CpG islands. a Clustered feature interaction maps of spatial overlap between hypermethylated
aDMRs (columns) and a selection of genomic, histone and transcription factor features (rows), showing WT (WT; left) and dwarf (D; centre left) aDMRs.
Red indicates an overlap between an aDMR and a feature and blue no overlap. Interaction map x-axes are scaled by number of aDMRs. The percentage
overlap (centre right) and fold enrichment observed/expected (random) overlap (right; units of fold) for each feature is given. b Percentage of WT and
Ames dwarf mice aDMRs that overlap with either histone modifications or a panel of 30 transcription factors (Histone or TF; blue) or neither (Neither;
red). c The base pair (in mega-base pairs) overlap between hypermethylated aDMR-containing CpG islands and hypermethylated aDMR-containing
bivalent regions in WT mice. Enrichment of overlap observed/expected 1302-fold, p < 0.001. d Kernel smoothed line plots of selected bivalent CpG
island (CpGI) overlapping hypermethylated aDMRs, ±5 kb. Replicates for 2-month-old WT (WT Young) and 22-month-old WT (WT Old) mice are
represented by solid blue and dashed blue lines, respectively. DMRs are highlighted in pink and CpGs in black. H3K4me3 and H3K27me3 enrichment
(ChIP-seq) is indicated. e Liver bivalent regions that contain hypermethylated aDMRs in WT and dwarf mice. Enrichment of overlap observed/expected
173-fold, p < 0.001. f Mean number of hypermethylated bivalent aDMRs per gene for WT (blue) and Ames dwarf (red) mice. Genes are split into
quartiles by expression (Q1= highest, Q4= lowest). Unexpressed genes (FPKM = 0) are given (U)
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dwarf compared to WT mice (Fig. 2b). These data
confirm that adult liver bivalent CpG islands that are
methylated during aging also tend to be methylated
in pre-cancerous liver.
Age-associated DNA methylation changes are also
suppressed by calorie restriction and rapamycin
As well as genetic interventions, dietary and drug inter-
ventions also promote longevity, healthy aging and
suppression of cancer. To test whether dietary and drug
interventions also suppress age-associated DNA methyla-
tion changes, we examined livers from female UM-HET3
mice treated with encapsulated rapamycin (42 mg/kg of
food) from 4 to 22 months’ of age and female mice on a
CR diet from 4 to 22 months’ of age [53–56]. We
performed WGBS-seq on DNA from whole liver, four
replicates per cohort, approximately 5× coverage per
sample (Additional file 4: Table S2). As controls for these
Fig. 5 Ames dwarf mice are resistant to cancer-like methylation changes during aging. a Mean methylation enrichment per probe (top panel) at
all probes within enhancers that contain WT hypomethylated aDMRs, for control (x-axis) and Mdr-2 knockout (KO; y-axis) mice. Numbers at top left
and bottom right show the number of probes above and below the dashed diagonal. The bottom panel shows the same data per mouse replicate.
*P < 0.05 (two tailed t-test). b As a but using enhancers containing WT hypermethylated aDMRs. **P < 0.01 (two tailed t-test). c As a but using bivalent
regions that contain WT hypermethylated aDMRs. **P < 0.01 (two tailed t-test). d As a but using enhancers that contain Ames dwarf hypomethylated
aDMRs. P > 0.05 (two tailed t-test). e As a but using enhancers that contain Ames dwarf hypermethylated aDMRs. **P < 0.01 (two tailed t-test).
f As a but using bivalent regions that contain Ames dwarf hypermethylated aDMRs. **P < 0.01 (two tailed t-test)
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UM-HET3 mice, we analyzed 2- and 22-month-old female
UM-HET3 mice fed ad libitum (ad lib; Fig. 2g; Additional
file 5: Figure S1a, b).
The mean global methylation level of each cohort
was very similar (72.72–73.35%) and also very similar
to the mean global methylation of the Ames dwarf mice
and corresponding WT (compare Fig. 1a to Fig. 6a). To
begin to assess the impact of CR and rapamycin on
age-associated methylation changes, we compared
hypomethylated and hypermethylated aDMRs between
young and old UM-HET3 mice (both fed ad lib) with
the same regions in rapamycin-treated and CR old
mice. At hypomethylated aDMRs, methylation loss was
suppressed by CR and, to a lesser extent, by rapamycin
(Fig. 6b; Additional file 3: Tables S6b and S5a–d;
Additional file 5: Figure S5a–d). At hypermethylated
aDMRs, methylation gain was also suppressed by CR,
but not significantly by rapamycin (Fig. 6c; Additional
file 3: Tables S5a, e–g; Additional file 5: S5a, e–g). At
these regions, the effect of rapamycin was not signifi-
cant in the whole population of hypermethylated
aDMRs (Fig. 6c; Additional File 3: Table S5a; Additional
file 5: Figure S5a), but was detectable in some individ-
ual aDMRs (Additional file 5: Figure S5f, g).
To assess where in the genome rapamycin and CR
suppress age-associated methylation changes, we gener-
ated clustered feature interaction maps depicting the gen-
omic distribution of regions where methylation changes
were suppressed by rapamycin and CR. CR suppressed
age-associated changes widely, including at genes, en-
hancers and CpG islands (Fig. 6d, e; Additional file 3:
Table S6d, e). Rapamycin suppressed age-associated
changes at a smaller number of genes, enhancers and
CpG islands (Fig. 6f, g; Additional file 3: Table S6f, g).
When averaged across a “composite” of all enhancers
hypomethylated with age, the suppression was similarly
more marked by CR than rapamycin (Fig. 6h). When
averaged across all hypermethylated bivalent regions, the
suppression by CR was readily apparent but modest,
whereas the suppression by rapamycin was undetectable
(Fig. 6i). In sum, while both CR and rapamycin suppressed
age-associated hypomethylation at enhancers, at least
under these protocols CR was more efficient than rapamy-
cin. CR also suppressed hypermethylation of some bi-
valent regions and CpG islands, while at these regions the
effect of rapamycin was detectable at a minority of regions
but not in all regions combined.
In addition to suppressing age-associated methylation
events, closer analysis revealed that both CR and rapamy-
cin caused a number of hypo- and hypermethylation
events that did not reflect a suppression of age-associated
changes (Additional file 5: Figure S5h). However, rapa-
mycin caused substantially more of these than did CR.
These non-age-related methylation changes were widely
distributed, including at genes, bivalent CpG islands
and enhancers (Additional file 5: Figure S5h).
Discussion
Here we have comprehensively mapped age-associated
changes in DNA methylation across all 42 million CpGs
of the genome by WGBS-seq of young and old mouse
liver. In analysis and interpretation of our data, we have
made extensive use of gene expression data and the
many epigenomic data sets publicly available for mouse
liver. Although we failed to observe global change in
DNA methylation, e.g. a global hypomethylation, we did
observe thousands of age-associated changes across
discrete regions of the genome. The greatest number of
such gains and losses of methylation occur at genes and
introns, although the number of these changes is in pro-
portion to the fraction of the genome occupied by those
features. Instead, losses of methylation are most enriched
at genic enhancers, including super-enhancers, within
genes highly expressed in liver, and gains of methylation
are most enriched at bivalent CpG islands. In sum, age-
associated changes in DNA methylation are most abun-
dant and/or enriched at various important functional and
regulatory regions of the genome.
What is the cause of these age-associated changes? It is
tempting to speculate that age-associated changes are
linked to the dynamic nature of these regulatory and
functional regions. These dynamic regions are maintained
at a steady state equilibrium that may change with age.
Expressed genes and enhancers are thought to be particu-
larly dynamic regions of the epigenome [57]. More specif-
ically, age-associated changes in DNA methylation might
be linked to age-associated changes in expression of the
cellular machinery that directly controls DNA methyla-
tion, such as DNMTs and TETs. Indeed, we have previ-
ously shown an age-associated increase and decrease in
expression of DNMT3a and DNMT1, respectively, in
mouse liver [45]. Alternatively, age-associated changes
in methylation might result from changes in metabolic
substrates and cofactors important for activity of DNMTs
and TETs, such as S-adenosylmethionine (SAM) and
α-ketoglutarate, respectively [58]. However, there must
also be additional sequence and/or epigenetic determi-
nants of methylation gains and losses to explain why some
regions, such as bivalent CpG islands, gain methylation
whereas others, such as enhancers, lose methylation
with age.
What is the consequence of these age-associated
changes in methylation? Losses of methylation at en-
hancers are only weakly linked to changes in expression
of linked genes, and some genes increase and others
decrease in expression. Recent studies suggested that
DNA methylation of enhancers is required for their
functional integrity [48, 59]. So, while age-associated
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Fig. 6 Age-associated DNA methylation changes are also suppressed by calorie restriction and rapamycin. a Global percentage methylation per
sample for 2- (Y) and 22-month-old (O) control, 22-month-old caloric restricted (CR) and 22-month-old rapamycin-treated (Rapa) UM-HET3 mice.
Part of this panel is reproduced from Additional file 5: Figure S1c. All p > 0.05 (two tailed t-test on arcsine transformed proportions). b Mean percentage
methylation per sample across all O-Y hypomethylated aDMRs for the samples in a. **Y versus O, Y versus Rapa, O versus CR, all p < 0.001; *Y versus CR,
O versus Rapa, CR versus Rapa, all p < 0.05 (two tailed t-test on arcsine transformed proportions). c Mean percentage methylation per sample across all
O-Y hypermethylated aDMRs for the samples in a. **Y versus O, Y versus Rapa, Y versus CR, all p < 0.001; *O versus CR, CR versus Rapa p < 0.05, O versus
Rapa p > 0.05 (two tailed t-test on arcsine transformed proportions). d Clustered feature interaction maps of spatial overlap between O-Y aDMRs
(columns) and a selection of genomic, histone and transcription factor features (rows), showing hypomethylated aDMRs that are also CR-O
hypermethylated DMRs (i.e. suppressed by CR); 1116 regions. e As d for O-Y hypermethylated aDMRs that are also CR-O hypomethylated DMRs
(i.e. suppressed by CR); 359 regions. f As d for O-Y hypomethylated aDMRs that are also Rapa-O hypermethylated DMRs (i.e. suppressed by
rapamycin); 330 regions. g As d for O-Y hypermethylated aDMRs that are also Rapa-O hypomethylated DMRs (i.e. suppressed by rapamycin);
225 regions. In d–g, the interaction map x-axes are scaled by number of aDMRs. h Composite profiles of mean percentage methylation at all
hypomethylated aDMR (Old-Young, UM-HET3 mice) enhancer regions (n = 1867), showing young (blue), old (black), CR (orange) and rapamycin-treated
(red). i Composite profiles of mean percentage methylation at hypermethylated aDMR (Old-Young) bivalent regions (n = 536), showing young (blue),
old (black), CR (green) and rapamycin-treated (red)
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loss of methylation at enhancers in these moderately
old mice (22 months old) is only modestly linked to
changes in gene expression, it is conceivable that this
methylation loss is a precursor to more dramatic
changes in methylation and expression in very old mice
or perhaps after tissue stress. In contrast to enhancers,
gains of DNA methylation at bivalent CpG islands are
not enriched for changes in gene expression. Most of
these genes are expressed at comparatively low levels
even in normal young tissue, and a gain of methylation
at the promoter CpG island is not expected to increase
their expression. Importantly, however, age-associated
changes at bivalent CpG islands are linked to hyperme-
thylation in cancer, suggesting that age-associated gain
in methylation can be a precursor to cancer, for ex-
ample by blocking activation of pro-differentiation and
development genes, as proposed previously [15, 18].
Age-associated changes in DNA methylation are sup-
pressed by genetic, dietary and drug interventions that ex-
tend lifespan and delay/suppress the incidence of cancer,
specifically the Prop1 mutation in the Ames dwarf mouse,
CR and rapamycin [1, 5]. Each of these interventions sup-
presses age-associated changes in methylation at genes,
enhancers and bivalent CpG islands. Consistent with the
aforementioned proposal that age-associated methylation
changes are linked to control of the DNA methylation
machinery and/or its metabolic regulators, Ames dwarf
mice do display atypical methionine metabolism, methio-
nine being a source of the SAM that is required for DNA
methylation. Components of this amino acid pathway are
upregulated in Ames mice, leading to higher enzyme activ-
ities, including of glycine N-methyltransferase (GNMT), an
enzyme that converts SAM to S-adenosyl-homocysteine
and sarcosine. Moreover, the methyltransferase enzymes
important in DNA methylation and methionine meta-
bolism are affected by the presence or absence of GH.
Methionine flux assays confirm the enhanced enzyme ac-
tivities, demonstrating that transmethylation and transsul-
phuration are markedly elevated in dwarf mice [60, 61].
Thus, elevated GNMT in Ames dwarf mice might depress
age-associated methylation of CpG islands, perhaps con-
tributing to delayed cancer incidence [2, 3]. Similarly, CR
and rapamycin might suppress the incidence of cancer
[5–7], at least in part, by suppressing methylation of
bivalent CpG island promoters. Aside from cancer sup-
pression, the other shared benefits of these genetic, dietary
and drug interventions for maintenance of tissue and sys-
temic function into old age might depend on suppression
of super-enhancer hypomethylation and so preservation
of tissue specific enhancer integrity, gene expression pro-
grams and tissue function [48]. Typically, the effect of CR
on the epigenome was greater than rapamycin, in line
with the greater extension of lifespan by CR than rapamy-
cin, at least under the protocols tested here [55, 56].
Notwithstanding the more efficient suppression of age-
associated epigenetic changes by CR, the epigenetic effects
of CR and rapamycin were not identical and this might fur-
ther underlie some of the differences between them that
have been noted in previous studies, for example in endo-
crine and metabolic phenotypes and gene expression pro-
files [55, 62]. Of note, rapamycin in particular appears to
induce additional changes unrelated to age-associated
changes. While both CR and rapamycin induced these
non-age-related effects, this effect was much more marked
for rapamycin. These non age-related epigenetic changes
include gains of methylation at genes, enhancers and CpG
islands and losses of methylation at genes and enhancers.
Conceivably, such non age-related effects of rapamycin in
liver and other tissues may contribute to at least some of
the well-documented harmful side effects of rapamycin,
such as glucose intolerance, increased incidence of testicu-
lar degeneration and cataracts [54, 55]. Detrimental effects
of rapamycin-like drugs, including dyslipidemia, hyperlipid-
emia and risk of diabetes, have also been noted in humans
[63, 64]. Of course, such adverse consequences of rapamy-
cin might also have a non-epigenetic basis. Regardless, this
study is a first comparison of the effect of diverse genetic,
dietary and drug interventions on the epigenetic landscape
and a foundation for understanding their influence on epi-
genetic determinants of chronological and biological aging.
Conclusions
We conclude that aging of mouse liver is associated with
marked DNA methylation changes to critical gene regu-
latory sequences, including gene promoters and en-
hancers of highly expressed genes. Distinct longevity-
promoting interventions, specifically genetic, dietary and
drug interventions, suppress some age-associated methy-
lation changes, consistent with the idea that these inter-
ventions exert their beneficial effects, in part, by
modulation of the epigenome. Together with the accom-
panying paper [65], our studies suggest that hypomethy-
lation of genic enhancers may constitute a biological age
clock that can predict liver function after stress.
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